Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about BIOMARKERS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | BIOMARKERS |
| Key Genes/Proteins | C1Q |
Knowledge base pages for this entity
graph TD
BIOMARKERS["BIOMARKERS"]
BIOMARKERS -.biomarker for.-> Neurocognitive_Disorders["Neurocognitive Disorders"]
BIOMARKERS -.biomarker for.-> Prostate_Cancer["Prostate Cancer"]
BIOMARKERS -->|"involved_in"| Tumor_Stage_Classification["Tumor Stage Classification"]
BIOMARKERS -->|"involved_in"| Prostate_Cancer_Prognosis_Pred["Prostate Cancer Prognosis Prediction"]
BIOMARKERS -->|"involved_in"| Prostate_Cancer_Early_Detectio["Prostate Cancer Early Detection"]
BIOMARKERS -.biomarker for.-> Hepatocellular_Carcinoma["Hepatocellular Carcinoma"]
BIOMARKERS -.biomarker for.-> Inclusion_Body_Myositis["Inclusion Body Myositis"]
BIOMARKERS -->|"involved_in"| Clinical_Treatment_Selection["Clinical Treatment Selection"]
Cytokines["Cytokines"] -.biomarker for.-> BIOMARKERS
Neuroinflammation["Neuroinflammation"] -.biomarker for.-> BIOMARKERS| Target | Relation | Type | Str |
|---|---|---|---|
| Neurocognitive Disorders | biomarker_for | disease | 0.95 |
| Prostate Cancer | biomarker_for | disease | 0.95 |
| Tumor Stage Classification | involved_in | process | 0.90 |
| Frailty | biomarker_for | disease | 0.90 |
| Prostate Cancer Early Detection | involved_in | process | 0.90 |
| Prostate Cancer Prognosis Prediction | involved_in | process | 0.90 |
| Early Disease Detection | involved_in | process | 0.90 |
| ALS | biomarker_for | disease | 0.90 |
| Disease-Modifying Treatment | associated_with | process | 0.90 |
| Hepatocellular Carcinoma | biomarker_for | disease | 0.88 |
| Early Detection | contributes_to | phenotype | 0.85 |
| Inclusion Body Myositis | biomarker_for | disease | 0.85 |
| Clinical Treatment Selection | involved_in | process | 0.85 |
| Accurate Diagnosis | involved_in | process | 0.85 |
| Neurodegenerative Diseases | biomarker_for | disease | 0.80 |
| Patient Management | associated_with | process | 0.80 |
| Amyotrophic Lateral Sclerosis | biomarker_for | disease | 0.80 |
| Sepsis Diagnosis | associated_with | phenotype | 0.80 |
| Neurodegenerative Diseases | associated_with | disease | 0.80 |
| Neurodegeneration Pathology | associated_with | process | 0.80 |
| Sepsis-Induced Immunosuppression | biomarker_for | process | 0.75 |
| Antibiotic Therapy | regulates | process | 0.75 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Cytokines | biomarker_for | process | 0.90 |
| biomarkers-4r-tauopathy-differential-biomarkers | describes | wiki | 0.90 |
| Prostate Cancer Immunotherapy | associated_with | drug | 0.85 |
| Proteomics | associated_with | process | 0.85 |
| Longevity Interventions | associated_with | process | 0.80 |
| Alzheimer's Disease | associated_with | disease | 0.80 |
| NEURODEGENERATIVE DISORDERS | markers | gene | 0.80 |
| Frailty | correlates_with | disease | 0.75 |
| Neuroinflammation | biomarker_for | process | 0.75 |
| Sweat | associated_with | entity | 0.75 |
| Serum | associated_with | entity | 0.75 |
| Saliva | associated_with | entity | 0.75 |
| C1Q | associated_with | protein | 0.56 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| APOE ε4-driven microglial lipid handling as proximal driver | 0.626 | neurodegeneration | Non-Neuronal Transcriptional Changes Pre |
| Cell-state stratification is required to resolve Non-Neurona | 0.612 | neurodegeneration | Non-Neuronal Transcriptional Changes Pre |
| Perturbation-first validation should precede therapeutic cla | 0.608 | neurodegeneration | Non-Neuronal Transcriptional Changes Pre |
| Disease-Elevated CHI3L1/CHIT1 Chitinases Are Biomarkers and | 0.502 | ALS | What are the mechanisms by which microgl |
| tight-junction remodeling is the actionable driver in: Blood | 0.362 | neurodegeneration | Blood-brain barrier permeability changes |
| endothelial transcytosis defines the therapeutic window for: | 0.357 | neurodegeneration | Blood-brain barrier permeability changes |
| plasma GFAP separates causal from compensatory states in: Bl | 0.346 | neurodegeneration | Blood-brain barrier permeability changes |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Crossing the blood-brain barrier: emerging therapeutic strategies for neurologic [PMID:39862873] | Pedder JH, Sonabend AM, Cearns MD | Lancet Neurol | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal gangli [PMID:40345829] | Shi, Sato, Takahashi, Ohno-Ohishi, Muray | Life science alliance | 2025 | 0 |
| The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegen [PMID:40468412] | Karunakaran Devi Krishna Priya; Ley Make | Molecular neurodegeneration | 2025 | 0 |
| AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal gangli [PMID:40345829] | Unknown | Life science alliance | 2025 | 0 |
| The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegen [PMID:40468412] | Karunakaran DKP, Ley M, Guo J, Khatri A, | Molecular neurodegeneration | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Blood-brain barrier biomarkers. [PMID:38797540] | Zapata-Acevedo JF, Mantilla-Galindo A, V | Adv Clin Chem | 2024 | 0 |
| Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Ne [PMID:39441380] | Taheri M, Roghani M, Sedaghat R | Cellular and molecular neurobi | 2024 | 0 |
| Endothelial Cell Senescence Effect on the Blood-Brain Barrier in Stroke and Cogn [PMID:39541552] | Real MGC, Falcione SR, Boghozian R | Neurology | 2024 | 0 |
| Blood-brain barrier biomarkers. [PMID:38797540] | Zapata-Acevedo JF, Mantilla-Galindo A, V | Advances in clinical chemistry | 2024 | 0 |
| Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Ne [PMID:39441380] | Taheri M, Roghani M, Sedaghat R | Cellular and molecular neurobi | 2024 | 0 |
| Endothelial Cell Senescence Effect on the Blood-Brain Barrier in Stroke and Cogn [PMID:39541552] | ["Real Maria Guadalupe C", "Falcione Sar | Neurology | 2024 | 0 |
| Dual-targeting of brain tumors with nanovesicles. [PMID:36816997] | Kianinejad N, Kwon YM | Bioimpacts | 2023 | 0 |
| Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer's Diseas [PMID:35008731] | Unknown | International journal of molec | 2022 | 0 |
| Post-Ischemic Neurodegeneration of the Hippocampus Resembling Alzheimer's Diseas [PMID:35008731] | Pluta, Januszewski, Czuczwar | International journal of molec | 2022 | 0 |
| Glymphatic system clears extracellular tau and protects from tau aggregation and [PMID:35212707] | Ishida K, Yamada K, Nishiyama R, Hashimo | The Journal of experimental me | 2022 | 0 |
| Glymphatic system clears extracellular tau and protects from tau aggregation and [PMID:35212707] | Ishida K, Yamada K, Nishiyama R, Hashimo | The Journal of experimental me | 2022 | 0 |
| Peripheral inflammation and blood-brain barrier disruption: effects and mechanis [PMID:33381913] | Huang X, Hussain B, Chang J | CNS Neurosci Ther | 2021 | 0 |
| Strategies for delivering therapeutics across the blood-brain barrier. [PMID:33649582] | Terstappen GC, Meyer AH, Bell RD | Nat Rev Drug Discov | 2021 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning BIOMARKERS in their description or question text
Score: 0.357 · neurodegeneration · 2026-04-26
The same signal may be beneficial early and damaging late. Testing endothelial transcytosis with pericyte-protective dos
Score: 0.346 · neurodegeneration · 2026-04-26
A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. Th